Investigation of two novel biochemical markers of inflammation, matrix metalloproteinase and cathepsin generated fragments of C-reactive protein, in patients with ankylosing spondylitis.
暂无分享,去创建一个
M. Karsdal | C. Christiansen | P. Alexandersen | M. Larsen | G. Schett | K. Henriksen | D. Leeming | A. Bay-Jensen | H. Skjøt-Arkil | Q. Zheng | A. Nawrocki | D. V. Larsen | C. Zhang | D. Larsen | Y. Wang | A. Bay‐Jensen
[1] M. Karsdal,et al. Protein fingerprints - relying on and understanding the information of serological protein measurements. , 2011, Clinical biochemistry.
[2] M. Karsdal,et al. Biochemical markers of ongoing joint damage in rheumatoid arthritis - current and future applications, limitations and opportunities , 2011, Arthritis research & therapy.
[3] M. Karsdal,et al. Enzyme-linked immunosorbent assay (ELISAs) for metalloproteinase derived type II collagen neoepitope, CIIM--increased serum CIIM in subjects with severe radiographic osteoarthritis. , 2011, Clinical biochemistry.
[4] A. Hashiramoto,et al. Pathogenesis of Joint Destruction in Rheumatoid Arthritis , 2011, Archivum Immunologiae et Therapiae Experimentalis.
[5] T. Moilanen,et al. Leptin enhances MMP-1, MMP-3 and MMP-13 production in human osteoarthritic cartilage and correlates with MMP-1 and MMP-3 in synovial fluid from OA patients. , 2011, Clinical and experimental rheumatology.
[6] R. Schiotis,et al. Relative value of the lumbar spine and hip bone mineral density and bone turnover markers in men with ankylosing spondylitis , 2011, Clinical Rheumatology.
[7] M. Karsdal,et al. Macrophage-mediated proteolytic remodeling of the extracellular matrix in atherosclerosis results in neoepitopes: a potential new class of biochemical markers. , 2010, Assay and drug development technologies.
[8] K. Vlam. Soluble and tissue biomarkers in ankylosing spondylitis. , 2010 .
[9] M. Karsdal,et al. Matrix metalloproteinase‐9‐mediated type III collagen degradation as a novel serological biochemical marker for liver fibrogenesis , 2010, Liver international : official journal of the International Association for the Study of the Liver.
[10] M. Karsdal,et al. Enzyme-linked immunosorbent serum assays (ELISAs) for rat and human N-terminal pro-peptide of collagen type I (PINP)--assessment of corresponding epitopes. , 2010, Clinical biochemistry.
[11] M. Karsdal,et al. Novel combinations of Post-Translational Modification (PTM) neo-epitopes provide tissue-specific biochemical markers--are they the cause or the consequence of the disease? , 2010, Clinical biochemistry.
[12] M. Karsdal,et al. A novel assay for extracellular matrix remodeling associated with liver fibrosis: An enzyme-linked immunosorbent assay (ELISA) for a MMP-9 proteolytically revealed neo-epitope of type III collagen. , 2010, Clinical biochemistry.
[13] J. Piette,et al. Serum cartilage oligomeric matrix protein (COMP) level is a marker of disease activity in relapsing polychondritis. , 2010, Clinical and experimental rheumatology.
[14] M. Karsdal,et al. Human macrophage foam cells degrade atherosclerotic plaques through cathepsin K mediated processes , 2010, BMC cardiovascular disorders.
[15] A. Mobasheri,et al. Targeting matrix metalloproteinases in inflammatory conditions. , 2009, Current drug targets.
[16] J. Zwerina,et al. Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. , 2009, Arthritis and rheumatism.
[17] T. Sawai,et al. Examination of in vivo gelatinolytic activity in rheumatoid arthritis synovial tissue using newly developed in situ zymography and image analyzer. , 2009, Clinical and experimental rheumatology.
[18] M. Karsdal,et al. Biochemical markers and the FDA Critical Path: How biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development , 2009, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.
[19] A. Hamzaoui,et al. Elevated levels of MMP-9 and TIMP-1 in the cerebrospinal fluid of neuro-Behçet's disease. , 2009, Clinical and experimental rheumatology.
[20] J. Shaughnessy,et al. The role of Dickkopf-1 in bone development, homeostasis, and disease. , 2009, Blood.
[21] Martin R Larsen,et al. The use of titanium dioxide micro-columns to selectively isolate phosphopeptides from proteolytic digests. , 2009, Methods in molecular biology.
[22] D. Wendling,et al. Serum levels of MMP-3 and cathepsin K in patients with ankylosing spondylitis: effect of TNFalpha antagonist therapy. , 2008, Joint, bone, spine : revue du rhumatisme.
[23] M. Karsdal,et al. Characterization of metalloprotease cleavage products of human articular cartilage. , 2008, Arthritis and rheumatism.
[24] Claus Christiansen,et al. Cartilage degradation is fully reversible in the presence of aggrecanase but not matrix metalloproteinase activity , 2008, Arthritis research & therapy.
[25] E. Vignon,et al. Serum concentrations of type II collagen biomarkers (C2C, C1, 2C and CPII) suggest different pathophysiologies in patients with hip osteoarthritis. , 2008, Clinical and experimental rheumatology.
[26] M. Karsdal,et al. Characterization of osteoclasts derived from CD14+ monocytes isolated from peripheral blood , 2006, Journal of Bone and Mineral Metabolism.
[27] M. Karsdal,et al. Relative contribution of matrix metalloprotease and cysteine protease activities to cytokine-stimulated articular cartilage degradation. , 2006, Osteoarthritis and cartilage.
[28] D J Hunter,et al. Classification of osteoarthritis biomarkers: a proposed approach. , 2006, Osteoarthritis and cartilage.
[29] C. Chou,et al. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity. , 2006, Rheumatology.
[30] J. Houwing-Duistermaat,et al. Urinary CTX-II levels are associated with radiographic subtypes of osteoarthritis in hip, knee, hand, and facet joints in subject with familial osteoarthritis at multiple sites: the GARP study , 2005, Annals of the rheumatic diseases.
[31] T. Cawston,et al. Matrix metalloproteinase knockout studies and the potential use of matrix metalloproteinase inhibitors in the rheumatic diseases. , 2005, Current drug targets. Inflammation and allergy.
[32] R. Bräuer,et al. Local expression of matrix metalloproteinases, cathepsins, and their inhibitors during the development of murine antigen-induced arthritis , 2004, Arthritis research & therapy.
[33] M. Pepys,et al. C-reactive protein and cardiovascular disease: new insights from an old molecule. , 2003, QJM : monthly journal of the Association of Physicians.
[34] M. Karsdal,et al. The Type I Collagen Fragments ICTP and CTX Reveal Distinct Enzymatic Pathways of Bone Collagen Degradation , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[35] J. Volanakis,et al. Human C-reactive protein: expression, structure, and function. , 2001, Molecular immunology.
[36] C Combet,et al. NPS@: network protein sequence analysis. , 2000, Trends in biochemical sciences.
[37] T. D. Du Clos. Function of C-reactive protein , 2000, Annals of medicine.
[38] G. Stucki,et al. Validity aspects of erythrocyte sedimentation rate and C-reactive protein in ankylosing spondylitis: a literature review. , 1999, The Journal of rheumatology.
[39] M. Dougados,et al. Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. , 1999, The Journal of rheumatology.
[40] M. Bissell,et al. An odyssey from breast to bone: Multi‐step control of mammary metastases and osteolysis by matrix metalloproteinases , 1999, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[41] J. Mathews,et al. Lack of correlation between clinical disease activity and erythrocyte sedimentation rate, acute phase proteins or protease inhibitors in ankylosing spondylitis. , 1986, British journal of rheumatology.
[42] D. Margulies,et al. A simple method for polyethylene glycol-promoted hybridization of mouse myeloma cells , 1977, Somatic cell genetics.
[43] E. Kass. The pathogenesis of ankylosing spondylitis. , 1975, Annals of clinical research.